Ashish Juvekar

1.8k total citations
22 papers, 1.3k citations indexed

About

Ashish Juvekar is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ashish Juvekar has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Ashish Juvekar's work include NF-κB Signaling Pathways (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Ashish Juvekar is often cited by papers focused on NF-κB Signaling Pathways (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Ashish Juvekar collaborates with scholars based in United States, Belgium and South Korea. Ashish Juvekar's co-authors include John M. Asara, Lewis C. Cantley, Costas A. Lyssiotis, Gerburg M. Wulf, Evan C. Lien, Hai Hu, Alex Toker, Hai Hu, Laura N. Burga and Ivana Vancurova and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Ashish Juvekar

22 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashish Juvekar United States 11 804 468 316 184 131 22 1.3k
Jianghong Deng China 21 1.2k 1.5× 596 1.3× 337 1.1× 179 1.0× 182 1.4× 54 1.9k
Doris R. Siwak United States 18 1.2k 1.4× 462 1.0× 224 0.7× 126 0.7× 213 1.6× 27 1.7k
Diana J. Azzam United States 13 1.1k 1.4× 549 1.2× 618 2.0× 236 1.3× 127 1.0× 23 1.6k
Kang Jin Jeong United States 23 1.3k 1.6× 492 1.1× 481 1.5× 166 0.9× 145 1.1× 32 1.7k
Steven A. Enkemann United States 18 783 1.0× 414 0.9× 246 0.8× 185 1.0× 121 0.9× 31 1.3k
Vera Levina United States 13 581 0.7× 688 1.5× 296 0.9× 178 1.0× 141 1.1× 18 1.1k
Sebastian Oeck Germany 17 907 1.1× 379 0.8× 322 1.0× 129 0.7× 248 1.9× 30 1.3k
Oona Delpuech United Kingdom 20 1.1k 1.3× 433 0.9× 460 1.5× 141 0.8× 243 1.9× 33 1.7k
Meilan Liu United States 18 995 1.2× 575 1.2× 427 1.4× 195 1.1× 292 2.2× 46 1.6k
Xiao-Feng Le United States 21 910 1.1× 462 1.0× 274 0.9× 111 0.6× 92 0.7× 23 1.3k

Countries citing papers authored by Ashish Juvekar

Since Specialization
Citations

This map shows the geographic impact of Ashish Juvekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Juvekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Juvekar more than expected).

Fields of papers citing papers by Ashish Juvekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish Juvekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Juvekar. The network helps show where Ashish Juvekar may publish in the future.

Co-authorship network of co-authors of Ashish Juvekar

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Juvekar. A scholar is included among the top collaborators of Ashish Juvekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Juvekar. Ashish Juvekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huarte, Eduardo, Michael T. Peel, Ashish Juvekar, et al.. (2021). Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Acute and Chronic Steroid-Refractory Gvhd Mouse Models. Immunotherapy. 13(12). 977–987. 4 indexed citations
2.
Huarte, Eduardo, Roddy S. O’Connor, Michael T. Peel, et al.. (2020). Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clinical Cancer Research. 26(23). 6299–6309. 67 indexed citations
3.
Yeleswaram, Swamy, Paul Smith, Timothy C. Burn, et al.. (2020). Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clinical Immunology. 218. 108517–108517. 70 indexed citations
4.
5.
6.
7.
Ruggeri, Bruce, Matthew C. Stubbs, Ashish Juvekar, et al.. (2017). Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification. Cancer Research. 77(13_Supplement). 1234–1234. 6 indexed citations
8.
Lien, Evan C., Costas A. Lyssiotis, Ashish Juvekar, et al.. (2016). Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nature Cell Biology. 18(5). 572–578. 202 indexed citations
9.
Hu, Hai, Ashish Juvekar, Costas A. Lyssiotis, et al.. (2016). Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. Cell. 164(3). 433–446. 289 indexed citations
10.
Juvekar, Ashish, Hai Hu, Sina Yadegarynia, et al.. (2016). Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proceedings of the National Academy of Sciences. 113(30). E4338–47. 71 indexed citations
11.
Hu, Hai, Ashish Juvekar, Costas A. Lyssiotis, et al.. (2014). Phosphoinositide 3-Kinase regulates glycolysis through mobilization of Aldolase A from the actin cytoskeleton. Cancer & Metabolism. 2(S1). 23 indexed citations
12.
Wulf, Gerburg M., Ashish Juvekar, Costas A. Lyssiotis, et al.. (2014). Abstract CT338: Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer. Cancer Research. 74(19_Supplement). CT338–CT338. 2 indexed citations
13.
Juvekar, Ashish & Gerburg M. Wulf. (2013). Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors. Breast Cancer Research. 15(2). 308–308. 5 indexed citations
14.
Juvekar, Ashish, Laura N. Burga, Hai Hu, et al.. (2012). Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. Cancer Discovery. 2(11). 1048–1063. 336 indexed citations
15.
Juvekar, Ashish, et al.. (2011). Electrophoretic Mobility Shift Assay Analysis of NFκB Transcriptional Regulation by Nuclear IκBα. Methods in molecular biology. 809. 49–62. 6 indexed citations
16.
17.
Ramaswami, Sitharam, Subrata Manna, Ashish Juvekar, et al.. (2011). Chromatin Immunoprecipitation Analysis of NFκB Transcriptional Regulation by Nuclear IκBα in Human Macrophages. Methods in molecular biology. 809. 121–134. 10 indexed citations
18.
Ghosh, Chandra C., Sitharam Ramaswami, Ashish Juvekar, et al.. (2010). Gene-Specific Repression of Proinflammatory Cytokines in Stimulated Human Macrophages by Nuclear IκBα. The Journal of Immunology. 185(6). 3685–3693. 50 indexed citations
19.
Ramaswami, Sitharam, et al.. (2009). Role of Acetylation in the NFkB Dependent Transcription of Proinflammatory Cytokines in Stimulated Human Macrophages. The FASEB Journal. 23(S1). 1 indexed citations
20.
Juvekar, Ashish, et al.. (2008). Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IκBα. Archives of Biochemistry and Biophysics. 475(2). 156–163. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianghong Deng Breakdown of academic impact, for papers by Doris R. Siwak Breakdown of academic impact, for papers by Diana J. Azzam Breakdown of academic impact, for papers by Kang Jin Jeong Breakdown of academic impact, for papers by Steven A. Enkemann Breakdown of academic impact, for papers by Vera Levina Breakdown of academic impact, for papers by Sebastian Oeck Breakdown of academic impact, for papers by Oona Delpuech Breakdown of academic impact, for papers by Meilan Liu Breakdown of academic impact, for papers by Xiao-Feng Le
Rankless by CCL
2026